📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. (2021)

First Author: Kolamunnage-Dona R
Attributed to:  EPSRC Centre for New Mathematical Sciences Capabilities for Healthcare Technologies funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jhep.2021.05.015

PubMed Identifier: 34052255

Publication URI: http://europepmc.org/abstract/MED/34052255

Type: Journal Article/Review

Volume: 75

Parent Publication: Journal of hepatology

Issue: 4

ISSN: 0168-8278